CJC-1295 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

CJC-1295 for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A lab-made, long-acting copy of the body's own growth-hormone signal. Its one proven effect in people is reliably raising growth hormone and its downstream messenger for many days per injection. Hoped-for gains in body composition, recovery, sleep, and slower aging remain largely unproven, and product quality varies widely by source. (Full Review)

Protocol

Dosing
Once or twice weekly injection
Subcutaneous, with-DAC form; exploits the 6–8 day half-life
Timing
Evening, on empty stomach
Aligns with the nocturnal GH surge; away from high-carbohydrate meals
Titration
Titrate to age-appropriate IGF-1
Start low; anchor dose to baseline IGF-1 rather than a fixed target
Time to effect
Hormonal rise
Within days
Rising IGF-1 begins within days of the first dose
Steady state
4–6 weeks
IGF-1 plateaus over roughly 4–6 weeks of regular dosing
Perceived effects
Weeks to months
Sleep or body-composition changes, if they occur, are not well characterized

Benefits

Contraindications
  • Active or recent cancer, or high cancer risk
  • Active proliferative diabetic retinopathy
  • Pregnancy or breastfeeding
  • Acromegaly or pituitary tumors
  • Uncontrolled diabetes (HbA1c >8%)
  • Severe untreated sleep apnea
  • Inability to obtain from a quality-assured source
    •
Key Interactions
  • Growth hormone secretagogues (ipamorelin, GHRP-6, GHRP-2, MK-677)
  • Exogenous growth hormone or other GHRH analogs (sermorelin, tesamorelin)
  • Insulin and antidiabetic drugs (metformin, sulfonylureas, GLP-1 agonists)
  • Corticosteroids (prednisone, dexamethasone)
  • Thyroid hormone
  • GH-axis or blood-sugar supplements (high-dose arginine, glutamine, GABA, berberine, chromium)
  • Over-the-counter medications (NSAIDs, oral decongestants)
    •

Risk & Side Effects

  • High: Product quality, contamination, and immunogenicity risk; injection site reactions
    •
  • Medium: Fluid retention and edema; impaired glucose tolerance and insulin resistance
    •
  • Low: Cardiovascular and vasomotor effects
    •
  • Speculative: Long-term cancer risk from elevated IGF-1
    •

Monitoring

Marker Target Why
IGF-1 Upper-mid of age- and sex-adjusted range; avoid exceeding upper limit Primary efficacy and safety marker; reflects GH stimulation
Fasting glucose 70–90 mg/dL GH opposes insulin and can raise glucose
HbA1c <5.4% Detects worsening glucose control over ~3 months
Fasting insulin 2–5 µIU/mL Early signal of GH-driven insulin resistance
IGFBP-3 Age-adjusted mid-range Binding protein for IGF-1; helps interpret GH-axis activity

Cadence: Baseline, ~6–8 weeks after starting or changing dose, then every 3–6 months

Qualitative Assessment

  • Sleep quality and depth (whether deep sleep feels improved or disrupted)
  • Energy levels and daytime vitality
  • Recovery from exercise and soft-tissue soreness
  • Body composition changes (subjective lean/fat shifts)
  • Swelling, puffiness, joint aching, or tingling in the hands (early fluid retention)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.